| __timestamp | Madrigal Pharmaceuticals, Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 15746000 | 11606000000 |
| Thursday, January 1, 2015 | 13392000 | 10313000000 |
| Friday, January 1, 2016 | 9290000 | 9762000000 |
| Sunday, January 1, 2017 | 7672000 | 9830000000 |
| Monday, January 1, 2018 | 15293000 | 10102000000 |
| Tuesday, January 1, 2019 | 22648000 | 10615000000 |
| Wednesday, January 1, 2020 | 21864000 | 8955000000 |
| Friday, January 1, 2021 | 37318000 | 9634000000 |
| Saturday, January 1, 2022 | 48130000 | 10042000000 |
| Sunday, January 1, 2023 | 108146000 | 10504000000 |
Cracking the code
In the ever-evolving pharmaceutical industry, operational costs play a pivotal role in shaping a company's financial health. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry titans: Merck & Co., Inc. and Madrigal Pharmaceuticals, Inc., from 2014 to 2023.
Merck, a global leader, consistently reported SG&A expenses exceeding $10 billion annually, reflecting its expansive operations and market reach. In contrast, Madrigal, a smaller player, saw its SG&A expenses grow by over 500% during the same period, peaking at approximately $108 million in 2023. This stark difference highlights the diverse strategies and scales of these companies.
Understanding these trends offers valuable insights into how pharmaceutical companies allocate resources to maintain competitiveness and drive innovation in a rapidly changing landscape.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Madrigal Pharmaceuticals, Inc.
Bio-Techne Corporation or Madrigal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Madrigal Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?